These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing? Yin C; Harms AC; Hankemeier T; Kindt A; de Lange ECM Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902391 [TBL] [Abstract][Full Text] [Related]
24. Biomarkers in Sporadic and Familial Alzheimer's Disease. Lista S; O'Bryant SE; Blennow K; Dubois B; Hugon J; Zetterberg H; Hampel H J Alzheimers Dis; 2015; 47(2):291-317. PubMed ID: 26401553 [TBL] [Abstract][Full Text] [Related]
25. Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology. González-Domínguez R; Sayago A; Fernández-Recamales Á J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Dec; 1071():75-92. PubMed ID: 28189423 [TBL] [Abstract][Full Text] [Related]
26. The identification of a potential plasma metabolite marker for Alzheimer's disease by LC-MS untargeted metabolomics. Lin CH; Lin YN; Lane HY; Chen CJ J Chromatogr B Analyt Technol Biomed Life Sci; 2023 May; 1222():123686. PubMed ID: 37068461 [TBL] [Abstract][Full Text] [Related]
27. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177 [TBL] [Abstract][Full Text] [Related]
28. A multiomics approach to heterogeneity in Alzheimer's disease: focused review and roadmap. Badhwar A; McFall GP; Sapkota S; Black SE; Chertkow H; Duchesne S; Masellis M; Li L; Dixon RA; Bellec P Brain; 2020 May; 143(5):1315-1331. PubMed ID: 31891371 [TBL] [Abstract][Full Text] [Related]
29. UHPLC-QTOF/MS-based metabolomics investigation for the protective mechanism of Danshen in Alzheimer's disease cell model induced by Aβ Zhang M; Liu Y; Liu M; Liu B; Li N; Dong X; Hong Z; Chai Y Metabolomics; 2019 Jan; 15(2):13. PubMed ID: 30830431 [TBL] [Abstract][Full Text] [Related]
30. Targeted metabolomics study of early pathological features in hippocampus of triple transgenic Alzheimer's disease male mice. Zhao Y; Chen H; Iqbal J; Liu X; Zhang H; Xiao S; Jin N; Yao F; Shen L J Neurosci Res; 2021 Mar; 99(3):927-946. PubMed ID: 33197957 [TBL] [Abstract][Full Text] [Related]
31. Studies on diagnostic biomarkers and therapeutic mechanism of Alzheimer's disease through metabolomics and hippocampal proteomics. Lin W; Zhang J; Liu Y; Wu R; Yang H; Hu X; Ling X Eur J Pharm Sci; 2017 Jul; 105():119-126. PubMed ID: 28495476 [TBL] [Abstract][Full Text] [Related]
32. Blood-based diagnosis of Alzheimer's disease using fingerprinting metabolomics based on hydrophilic interaction liquid chromatography with mass spectrometry and multivariate statistical analysis. Inoue K; Tsuchiya H; Takayama T; Akatsu H; Hashizume Y; Yamamoto T; Matsukawa N; Toyo'oka T J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 974():24-34. PubMed ID: 25463194 [TBL] [Abstract][Full Text] [Related]
33. New Insights into lncRNAs in Aβ Cascade Hypothesis of Alzheimer's Disease. Hao Y; Xie B; Fu X; Xu R; Yang Y Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551230 [TBL] [Abstract][Full Text] [Related]
37. Pathogenesis, therapeutic strategies and biomarker development based on "omics" analysis related to microglia in Alzheimer's disease. Gao C; Shen X; Tan Y; Chen S J Neuroinflammation; 2022 Sep; 19(1):215. PubMed ID: 36058959 [TBL] [Abstract][Full Text] [Related]
38. Mass spectrometry-based urinary metabolomics for exploring the treatment effects of Radix ginseng-Schisandra chinensis herb pair on Alzheimer's disease in rats. Wang A; Pi Z; Liu S; Zheng Z; Liu Z; Song F J Sep Sci; 2021 Aug; 44(16):3158-3166. PubMed ID: 34110709 [TBL] [Abstract][Full Text] [Related]
39. Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. Qin T; Prins S; Groeneveld GJ; Van Westen G; de Vries HE; Wong YC; Bischoff LJM; de Lange ECM Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365768 [TBL] [Abstract][Full Text] [Related]
40. Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer's disease. González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL J Pharm Biomed Anal; 2015 Mar; 107():378-85. PubMed ID: 25656489 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]